

- The current analysis of data from the eXpeRience registry focuses on healthcare resource utilization and on absences from work or school.
- A total of 943 patients with omalizumab-treated uncontrolled persistent allergic asthma were recruited from 14 countries in Europe, North America and Asia.
- In comparison with the 12 month pre-treatment period, omalizumab therapy over 24 months was associated with:
 - reduced asthma-related hospitalizations, emergency room visits and unscheduled doctor visits
 - reduced missed work or school days due to asthma.
- In a real-life setting, add-on treatment with omalizumab was shown to reduce the direct and indirect costs of healthcare associated with this patient population.

This summary slide represents the opinions of the authors. Sponsorship for this registry was funded by Novartis Pharma AG, Basel, Switzerland. Medical writing assistance for this registry was provided by Santosh Tiwari and Richard Crampton (Novartis Pharma AG, Basel, Switzerland). For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).